April 16th 2024
Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Clarity Still Needed on Cetuximab Benefit in mCRC, Expert Says
December 23rd 2016Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.
Read More
Pembrolizumab Granted Priority Review from FDA for MSI-H Cancer
December 23rd 2016The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer.
Read More
The Possibility for Immunotherapy in Liver Cancer
December 15th 2016Tim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Oncology Branch, and head, Gastrointestinal Malignancy Section, National Cancer Institute Center for Cancer Research, discusses the possibility for immunotherapy in liver cancer.
Watch
Tackling Some of The Challenges That Remain in Pancreatic Cancer
November 16th 2016Howard S. Hochster, MD, professor of Medical Oncology, and Yale Cancer Center Associate Director (for Clinical Sciences), discusses steps that can be taken to tackle some of the challenges that remain in the field of pancreatic cancer.
Watch
Early Support for Immunotherapy/Standard Therapy Combos in HCC
November 8th 2016Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma (HCC), according to a leading liver immunology expert.
Read More
Dafna Bar-Sagi Honored With Oustanding Investigator Award From NCI
October 31st 2016Dafna Bar-Sagi, PhD, vice dean for science and chief scientific officer of NYU Langone Medical Center, and a senior member of its Perlmutter Cancer Center, was recently named a recipient of the Outstanding Investigator Award from the National Cancer Institute (NCI).
Read More
How Mutation Status Affects Individualization of Treatment in mCRC
October 28th 2016Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).
Watch
European Commission Approves Liposomal Irinotecan Combo for Pancreatic Cancer
October 27th 2016Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.
Read More
New CRC Treatment Options May Emerge From Mutation Discordance Findings
October 24th 2016Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.
Read More
CVS Cuts Out In-House Dispensaries of Cancer Drugs
October 20th 2016A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.
Read More
The Need for Better Surrogate Parameters for Overall Survival in Colorectal Cancer
October 3rd 2016Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.
Watch
Expert Discusses New Targets, Developments on the Horizon in Gastric Cancer
September 27th 2016As gastric cancers continue to be classified into different subtypes, oncologists will now have the opportunity to improve treatment by determining which targeted agents are appropriate for which subtypes, said Howard S. Hochster, MD.<br />
Read More